Ampsource Biopharma Shanghai Inc.

Main purpose: To evaluate the safety and tolerability of AP025 50mg QW after repeated administration in subjects with dyslipidemia. Secondary purpose: To evaluate the pharmacokinetic properties of AP025 50 mg QW after multiple dosing in dyslipidemic subjects. Evaluation of the immunogenicity profile of AP025 50 mg QW after multiple doses in dyslipidemic subjects. To evaluate the pharmacodynamic profile of AP025 50mg QW after multiple doses in dyslipidemic subjects.

main purpose: To evaluate the effectiveness of TQA2225/AP025 in subjects with nonalcoholic steatohepatitis; Secondary purpose: To evaluate the safety of TQA2225/AP025 in subjects with nonalcoholic steatohepatitis. To evaluate the immunogenicity of TQA2225/AP025 in subjects with nonalcoholic steatohepatitis. To evaluate the pharmacokinetic (PK) characteristics of TQA2225/AP025 in subjects with nonalcoholic steatohepatitis.

main purpose To evaluate the safety and tolerance of single injection of different doses of AP017 monoclonal antibody injection in healthy subjects sex. secondary purpose 1) Evaluate the pharmacokinetics of single injection of different doses of AP017 monoclonal antibody injection in healthy subjects feature; 2) Evaluate the immunogenicity of a single injection of different doses of AP017 monoclonal antibody injection in healthy subjects; 3) To evaluate the pharmacodynamic characteristics of a single injection of different doses of AP017 monoclonal antibody injection in healthy subjects sign. exploratory purpose To explore the PK/PD correlation of single injection of different doses of AP017 monoclonal antibody injection in healthy subjects.